Cystic fibrosis-related diabetes and lung disease: an update. (17th February 2021)

• Record Type: Journal Article
• Authors: Prentice, Bernadette J.; Jaffe, Adam; Hameed, Shihab; Verge, Charles F.; Waters, Shafagh; Widger, John
• Is Part Of: European respiratory review. Volume 30:Number 159(2021)
• Publication Date: 2021-02-17
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0293-2020
• Languages: English
• ISSNs: 0905-9180

Abstract

The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD. Cystic fibrosis (CF)-related diabetes remains one of the most important comorbidities for patients with CF because of the impact on lung function and mortality. There are numerous factors in addition to infection that contribute to the negative effects of CF-related diabetes. https://bit.ly/3nSPFW6